Trial Profile
Open label study to establish the efficacy of intravenous loading doses of Ibandronate 6 mg in patients with lung cancer and skeletal metastased experiencing moderate to severe bone pain
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Ibandronic acid (Primary)
- Indications Bone metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 28 Mar 2024 Status changed from recruiting to discontinued.
- 09 Aug 2011 New trial record